Response rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials

dc.creatorSantos-Lozano A.
dc.creatorMorales-Gonzalez A.
dc.creatorSanchis-Gomar F.
dc.creatorCristi-Montero C.
dc.creatorFiuza-Luces C.
dc.creatorPareja-Galeano H.
dc.creatorMartínez-López J.
dc.creatorGaratachea N.
dc.creatorLucia A.
dc.date.accessioned2020-09-02T22:28:06Z
dc.date.accessioned2022-11-08T20:27:28Z
dc.date.available2020-09-02T22:28:06Z
dc.date.available2022-11-08T20:27:28Z
dc.date.created2020-09-02T22:28:06Z
dc.date.issued2016
dc.identifier105, , 118-126
dc.identifier10408428
dc.identifierhttps://hdl.handle.net/20.500.12728/6197
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5146458
dc.languageen
dc.publisherElsevier Ireland Ltd
dc.subjectMeta-analysis
dc.subjectPurine analogues
dc.subjectRituximab
dc.subjectWaldeström disease
dc.subjectbendamustine
dc.subjectbortezomib
dc.subjectcarfilzomib
dc.subjectcladribine
dc.subjectcyclophosphamide
dc.subjectdexamethasone
dc.subjectfludarabine
dc.subjectrituximab
dc.subjectdrug combination
dc.subjectcancer combination chemotherapy
dc.subjectdrug efficacy
dc.subjectdrug response
dc.subjecthuman
dc.subjectmeta analysis
dc.subjectmonotherapy
dc.subjectprogression free survival
dc.subjectReview
dc.subjecttreatment outcome
dc.subjectWaldenstroem macroglobulinemia
dc.subjectdrug combination
dc.subjectWaldenstrom Macroglobulinemia
dc.subjectDrug Combinations
dc.subjectHumans
dc.subjectTreatment Outcome
dc.subjectWaldenstrom Macroglobulinemia
dc.titleResponse rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials
dc.typeReview


Este ítem pertenece a la siguiente institución